AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Insilico Medicine vs Suki AI

Insilico Medicine

Insilico Medicine

VS
Suki AI

Suki AI

Verdict by Category

Detailed category analysis is not available for this comparison.
View Insilico Medicine View Suki AI

Detailed Comparison

Feature
Insilico Medicine
Suki AI
Pricing
CustomInsilico Medicine operates through two revenue streams: platform licensing and internal drug pipeline development. Platform access: Pharmaceutical and biotech companies license the Pharma.AI platform (PandaOmics, Chemistry42, InClinico) through enterprise agreements for target identification, molecule design, and clinical prediction. Revenue is structured as upfront platform fees, milestone payments tied to drug program progress, and royalties on commercialized drugs. Pipeline partnerships: Insilico licenses its AI-discovered drug candidates to pharma companies (e.g., Sanofi, Exelixis) for multi-million/billion dollar deals with upfront + milestone structures. Total revenue grew from $4.5M (2021) to $85M (2024). Contact Insilico through insilico.com for licensing and partnership inquiries.
CustomSuki does not publish pricing on its official website; every path (Suki for Clinicians and Suki for Partners) leads to a "Contact Us" sales conversation rather than a self-serve checkout. Third-party trade coverage and reseller listings throughout 2025-2026 consistently report two tiers: Suki Compose (documentation-only, works with any EHR) at roughly $299 per provider per month, and the full Suki Assistant (deep EHR integration, voice commands, coding, and clinical Q&A) at roughly $399 per provider per month. Enterprise health-system contracts are negotiated separately with volume and specialty-based discounts, and some independent reviews report additional setup fees in the $500-$2,000 range plus annual contract commitments. Exact pricing requires a conversation with Suki's sales team.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
Generative AI drug discovery platform — from target identification to Phase 3 clinical trials with Pharma.AI
Ambient clinical AI that turns patient visits into notes, coding, and voice-driven workflows
Insilico Medicine

Insilico Medicine Pros & Cons

Pros

  • World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
  • End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
  • 300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
  • Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
  • Automated robotic lab in Suzhou closing the loop between AI design and physical testing
  • Global presence: US, China, Canada, Middle East — with partnerships across big pharma
  • Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing

Cons

  • Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
  • Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
  • Dual-track model (platform + internal pipeline) adds operational complexity
  • Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
  • Listed on HKEX (Hong Kong) — less accessible to US institutional investors
Suki AI

Suki AI Pros & Cons

Pros

  • Genuine voice-command interface goes beyond passive transcription, letting clinicians drive the EHR by voice
  • Combines documentation, coding, and clinical Q&A in one platform instead of separate point tools
  • Deep, bi-directional integration with the four leading EHRs: Epic, Oracle Health, athenahealth, and MEDITECH
  • Backed by independent KLAS validation of clinical and financial ROI
  • Broad specialty and care-setting coverage, from ambulatory and inpatient to telehealth and home health
  • Suki for Partners lets healthtech companies embed the same ambient AI via APIs and SDKs

Cons

  • No public pricing or free tier; every path on the website leads to a sales demo and a typically annual enterprise contract
  • Reported per-provider pricing (roughly $299-$399/month) runs meaningfully higher than several budget-focused competitors
  • Enterprise-style deployment and contracting can be heavier than solo clinicians or small practices need
  • Learning the voice-command workflow adds a slight learning curve compared with purely passive ambient scribes
  • Doesn't cover adjacent front-office tasks like patient call answering, fax management, or payment collection